NY-THE-BODY-SHOP
9.1.2023 07:16:30 CET | Business Wire | Press release
Today is No Say Day - the last day in 2023 when young people’s voices are represented in parliaments around the world. This falls a week before world leaders and businesses gather in Davos for the World Economic Forum Annual Meeting. Often criticised for being out of touch, Davos is a prime example of the need for more youth voices in decision making spaces.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230108005001/en/
Antonia Tony-Fadipe, Inclusive Hiring Lead and The Body Shop Youth Collective member; Urvasi De Biasi, Activism Policy and Partnerships, The Body Shop; Lily Cannon, Activism Communications Manager, The Body Shop; Lucila San Martin, Global Activism Manager, The Body Shop (Photo: Business Wire)
Half of the world’s population is under 30, compared to just 2.6% of parliamentarians globally*. If this ratio were reflected in a year, youth voices would effectively go unheard after today. Just nine days into 2023, No Say Day is a stark demonstration of the fact that millions of young voices are excluded from decision-making spaces at a time when the world is facing extreme systemic challenges.
No Say Day is being marked as part of the Be Seen Be Heard campaign, led by The Body Shop in collaboration with the Office of the United Nations Secretary-General's Envoy on Youth to raise the voices of millions of young people in over 75 countries across six continents.
Public opinion is widely in favour of fairer political representation for young people. According to The Body Shop’s largest-ever global survey**, two thirds of people agree that the age balance in politics is wrong.
People across all age groups agree that political systems would be improved by giving young people a say in policy development. Young people are optimistic and determined to increase their involvement in public life. A third of those under age 30 surveyed would consider running for office, versus only a fifth of those over age 30.
Chris Davis, Global Sustainability and Activism Director at The Body Shop, said: “From climate change to economic instability and conflict, the world’s problems are too great to fall back on business-as-usual. Young people are energetic, thoughtful, and positive about the future – so it’s important their voices are seen and heard in parliaments around the world every day. This is clearly the preference of the public, who support a fairer approach to youth representation and trust young people’s views on the major issues of today.
“As world leaders and captains of industry gather in Davos next week, I urge them to work with young people to develop solutions to the problems we all face. Let’s make today the last No Say Day in our history.”
Jayathma Wickramanayake, the UN Secretary-General’s Envoy on Youth, said: “Young people are the experts of their own realities, and young people all over the world are making a difference every day by tackling issues that matter most to them. The idea that young people are change makers is not just a marketing campaign, it is a fact. We must dispel the myths surrounding young people, that they are irresponsible, disengaged, troublemakers, or do not have the experience to create real impact. Even in the most adverse of circumstances we have seen young people rising to the challenge and leading the way — from humanitarian crises to COVID-19 response. There is no doubt that we need young people’s innovation, drive, creativity and – more than anything – unwavering optimism that a better world is possible for everyone.”
ENDS
*https://www.ipu.org/our-impact/youth-empowerment/data-youth-participation
**The Be Seen Be Heard Global Youth Survey
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230108005001/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
